Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.
Researchers identified the prevalence of non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH) in individuals who are overweight or obese. ...
Emerging treatments have improved the standard of care for managing patients with both type 2 diabetes and obesity. Carol Wysham, MD, and Deborah B. Horn, DO, MPH, discuss these new treatments and...
